Respiri Limited has completed its acquisition of Orb Health Inc. for US$9 million in shares, marking a strategic move to strengthen its foothold in the US connected and chronic care market. The integration promises operational cost savings and expanded service offerings.
Immuron Limited reports a striking 70% quarter-on-quarter increase in Travelan® sales, driven by expanded pharmacy distribution in Australia and North America.
Orthocell Limited has reported a third consecutive quarter of record revenue, driven by strong sales growth and strategic market expansions, including a key US FDA submission for its nerve repair product Remplir™.
Pacific Edge faces a significant Medicare reimbursement setback as Novitas finalizes a non-coverage decision for its Cxbladder tests, prompting the company to activate legal challenges and operational restructuring.